Linked Life Data

18485581

Source:http://linkedlifedata.com/resource/pubmed/id/18485581

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-7-1
pubmed:abstractText
Metastatic renal cell carcinoma (mRCC) has long been treated only by immunotherapy with good results only in a small population of patients. In recent years, major improvements in treatment possibilities have occurred with the advent of anti-angiogenic drugs. In the past 2 yr, pivotal phase III trials have confirmed this major breakthrough by increasing the progression-free survival rates and/or overall survival rates provided by sunitinib, sorafenib, and bevacizumab, and more recently by the mTOR (mammalian target of rapamycin) inhibitors temsirolimus and everolimus.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1873-7560
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
315-25
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Update on the medical treatment of metastatic renal cell carcinoma.
pubmed:affiliation
Department of Medical Oncology, Hôpital Saint André, Bordeaux, France; University of Bordeaux 2 Victor Ségalen, Bordeaux, France.
pubmed:publicationType
Journal Article, Review